Vera Therapeutics enters the second week of July with a striking split: five analysts raised price targets on the same day the stock jumped 7%, yet short sellers are sitting on nearly 19% of the float with no sign of covering.
The analyst activity on July 8 was unusually concentrated. BofA Securities lifted its target from $65 to $70, maintaining Buy. Guggenheim made a larger move, raising its target from $56 to $76. TD Cowen went to $78 from $73, also keeping Buy. The consensus mean target now sits around $81.79 — roughly double the current price of $42.96 — which reflects how bullish the majority of the Street remains on atacicept's commercial potential in IgA nephropathy. The one dissenter in the group is Wedbush, which raised its Neutral target from $35 to $43 — essentially flagging the stock as fairly valued right now. That single Neutral rating captures the bear thesis neatly: the ORIGIN trial showed a lower UPCR reduction than competitor sibeprenlimab's 51.2%, and the company continues to burn cash with no revenue yet on the board.
Short positioning tells a story that cuts against the bullish analyst chorus. Short interest is running at 18.6% of the free float — nearly 11.9 million shares — and has climbed about 18% over the past month even as the stock rallied 33%. That is an unusual combination: shorts rebuilding into a rising price, either as a hedge against competitive risk or as a conviction bet that the atacicept label will underwhelm at approval. What makes this less combustible than it looks is the lending market. Availability is exceptionally loose at over 1,000% — meaning there are roughly ten shares available to borrow for every one already lent out — and the cost to borrow is negligible at 0.52%. Shorts face no material squeeze pressure at current levels. The ORTEX short score has eased from 64 in late June to around 62, consistent with a modest softening in short-side conviction rather than any structural shift.
Options positioning adds a nuance. The put/call ratio at 0.19 is well below its 52-week range midpoint and sits close to its 20-day average of 0.16 — well inside one standard deviation. Call flow dominates, consistent with the bullish analyst posture and a market that has been buying the atacicept story on each piece of positive data. Compare that with close peers: VKTX rose 8.8% on the day and 6.6% on the week, ALGS gained 12.2% over the week, and DYN added 12.1% — suggesting the broader clinical-stage biotech tape was supportive rather than VERA-specific on Tuesday's move.
On the ownership side, Deep Track Capital entered the top-five holders in Q1 with a near-4 million share position added from scratch, a meaningful vote of confidence from a specialist healthcare fund. BlackRock and State Street both added modestly through June 30. The CEO, Marshall Fordyce, has been a consistent seller under a 10b5-1 plan — roughly $700,000 in sales in late June alone — though at these volumes relative to the company's overall share count the transactions read as programmatic rather than directional.
Next up: Q2 results are scheduled for August 5. The prior four earnings prints have been mixed — a 7.8% day-one gain in May 2026, a 1.7% loss before that, and moves of roughly flat to slightly positive for earlier releases. With short interest elevated and the analyst community freshly raising targets, that print will be watched closely for any update on the atacicept regulatory timeline and cash runway.
See the live data behind this article on ORTEX.
Open VERA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
